Items home
EnglishFrenchDutchSpanishGermanItalianChineseTurkishPolishUSA
Najczęsciej zadawane pytania
Poprzednie panele EQA
Poprzednie raporty
Publikacje
Spotkania
Słownik
Linki

Sorry page translation is currently un-available

COVID-19 Notice

COVID-19 QCMD Notice to Our EQA/PT Participants and Interested Parties

Updated: 25th June 2020

We want to reassure you that QCMD continues to operate and to support you through these challenging times. Participants have been already informed by email regarding the changes to the QCMD EQA/PT schedule of affected programmes. We are continuously evaluating the global situation and its impacts, and will contact you further with any changes if necessary.

To support your laboratories EQA needs two new programmes have been announced – SARS-CoV-2 and Respiratory I plus

QCMD 2020 SARS-CoV-2 EQA Study (SCV2)

The SCV2_20 EQA panel is being provided in response to demand from participants within the initial ‘QCMD 2020 Coronavirus Outbreak Preparedness EQA Pilot Study (CVOP20S)’ from earlier this year. The EQA scheme will be offered in two formats; either a single 10 sample single challenge format or a two-challenge format with 5 samples per challenge.

The primary objective of this EQA scheme will be to assess laboratories in the molecular detection of SARS-CoV2 at clinically appropriate levels, near the Limit of detection of the assay as well as the specificity of molecular assay in the presence of other non-SARS Coronaviruses.

QCMD 2020 Respiratory I Plus (RESPIplus)

This year in addition to the RESPI EQA scheme which covers Influenza A, Influenza B, and RSV and is released prior to the annual influenza season an additional programme RESPIplus will also include SARS-CoV2 so that those laboratories using multiplex and/or cartridge based molecular systems will be able to review the performance of their molecular workflows in the detection and differentiation of SARS-CoV2 in combination with other respiratory pathogen targets.

Both EQA schemes will consist of inactivated whole pathogen SARS-CoV-2 material, which has been characterised across all gene targets using a broad range of molecular assays.

Please be assured that we are committed to support you and your laboratory in these times. We have taken the necessary measures for our staff and infrastructure, to remain active and maintain our full EQA services for all our participants worldwide. Therefore, please do not hesitate to contact us via the online ‘Contact Us’ form in ITEMS or on our website. We thank you for your continued support and we hope that the current situation improves soon.

QCMD

Unit 5, Technology Terrace, Todd Campus, West of Scotland Science Park Glasgow G20 0XA Scotland, UK
Tel: +44 (0)141 945 6474 Fax: +44 (0)141 945 5795 Enquiry Form